{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:03:02Z","timestamp":1780095782736,"version":"3.54.0"},"reference-count":20,"publisher":"Georg Thieme Verlag KG","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Was ist neu?<\/jats:title>\n                  <jats:p>Die aktuellen Leitlinien der Europ\u00e4ischen Gesellschaft f\u00fcr Kardiologie empfehlen die Anwendung von Herzglykosiden\/Digitalis bei Patienten mit Herzinsuffizienz bei einer LVEF \u226440% und Sinusrhythmus, wenn eine Symptomatik trotz Therapie mit Betablockern, ACE-Hemmern\/Angiotensin-Rezeptor-Neprilysin-Inhibitoren und Mineralokortikoidrezeptor-Antagonisten persistiert, um das Risiko weiterer Hospitalisierungen zu senken. Eine Therapie mit Herzglykosiden wird bei Herzinsuffizienz und einer LVEF &gt;40% und Sinusrhythmus nicht empfohlen. Bei Vorhofflimmern kann eine Therapie mit Herzglykosiden bei Herzinsuffizienz und einer LVEF &gt;40% zur Frequenzkontrolle gleichwertig zu Betablockern, Verapamil und Diltiazem eingesetzt werden, bei einer LVEF \u226440%, wenn die Frequenzkontrolle unter einer Betablockertherapie nicht ausreicht oder nicht m\u00f6glich ist.<\/jats:p>\n                  <jats:p>In der k\u00fcrzlich publizierten DIGIT-HF-Studie senkt Digitoxin in niedrigen Serumkonzentrationen die Mortalit\u00e4t jeglicher Ursache und die Herzinsuffizienz-bedingten Hospitalisierungen bei Patienten mit einer LVEF \u226440%, zus\u00e4tzlich zu einer sehr guten Leitlinien empfohlenen Pharmako- und Devicetherapie. Dabei profitieren sowohl Patienten mit Sinusrhythmus als auch Vorhofflimmern. Wichtige neue Studiendaten aus der DECISION-Studie, zur Anwendung von Digoxin bei Herzinsuffizienz werden f\u00fcr 2026 erwartet. Weitere Studien geben Hinweise auf g\u00fcnstige Effekte von Herzglykosiden auf pulmonal-arterielle Druckwerte bei Herzinsuffizienz und auf Surrogatmarker einer Herzinsuffizienz bei Vorhofflimmern.<\/jats:p>\n                  <jats:p>Digitoxin kann in niedrigen Serumkonzentrationen bei symptomatischer Herzinsuffizienz mit reduzierter Pumpfunktion zur Verbesserung der Prognose und Vermeidung von Herzinsuffizienz-bedingten Hospitalisierungen sicher eingesetzt werden. Insbesondere Patienten mit Vorhofflimmern, fortgeschrittener Herzinsuffizienzsymptomatik, niedrigem Blutdruck und h\u00f6heren Herzfrequenzen sollten mit Digitoxin behandelt werden sowie Patienten, bei denen der Einsatz der bisher empfohlenen Prognose verbessernden Pharmakotherapie limitiert ist. Herzglykoside sind eine wichtige und sichere Therapieoption zur Frequenzkontrolle bei Patienten mit Vorhofflimmern und Herzinsuffizienz. Die f\u00fcr 2026 erwarteten Studiendaten f\u00fcr Digoxin sind wichtig f\u00fcr die finale Bewertung zur Nutzung von Herzglykosiden bei Herzinsuffizienz.<\/jats:p>","DOI":"10.1055\/a-2676-2529","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T22:38:29Z","timestamp":1780094309000},"page":"633-638","source":"Crossref","is-referenced-by-count":0,"title":["Digitalis und Herzinsuffizienz"],"prefix":"10.1055","volume":"151","author":[{"given":"Udo","family":"Bavendiek","sequence":"additional","affiliation":[{"name":"Medizinische Hochschule Hannover, Germany","place":["Hannover"],"department":["Klinik f\u00fcr Kardiologie und Angiologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Bauersachs","sequence":"additional","affiliation":[{"name":"Medizinische Hochschule Hannover, Germany","place":["Hannover"],"department":["Klinik f\u00fcr Kardiologie und Angiologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199307013290101","article-title":"Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study","volume":"329","author":"M Packer","year":"1993","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/0735-1097(93)90403-n","article-title":"Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group","volume":"22","author":"BF Uretsky","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure","volume":"336","author":"G Digitalis Investigation","year":"1997","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1001\/jama.289.7.871","article-title":"Association of serum digoxin concentration and outcomes in patients with heart failure","volume":"289","author":"SS Rathore","year":"2003","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.jacc.2005.02.091","article-title":"Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis","volume":"46","author":"KF Adams Jr","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/eurjhf\/hft010","article-title":"Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial","volume":"15","author":"M Gheorghiade","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"TA McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00059-025-05327-9","article-title":"Diagnosis and treatment of heart failure with preserved ejection fraction","volume":"50","author":"S Soltani","year":"2025","journal-title":"Herz"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1161\/CIRCULATIONAHA.106.628347","article-title":"Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial","volume":"114","author":"A Ahmed","year":"2006","journal-title":"Circulation"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"IC Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1001\/jama.2020.23138","article-title":"Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial","volume":"324","author":"D Kotecha","year":"2020","journal-title":"JAMA"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/eurheartj\/ehi687","article-title":"Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial","volume":"27","author":"A Ahmed","year":"2006","journal-title":"Eur Heart J"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/ejhf.1452","article-title":"Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study","volume":"21","author":"U Bavendiek","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"03","key":"ref14","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/ejhf.3575","article-title":"The DIGIT-HF trial: Key amendments of study design","volume":"27","author":"U Bavendiek","year":"2025","journal-title":"Eur J Heart Fail"},{"issue":"07","key":"ref15","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/ejhf.3679","article-title":"DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure (DIGIT-HF): Baseline characteristics compared to recent randomized controlled heart failure trials","volume":"27","author":"U Bavendiek","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1056\/NEJMoa2415471","article-title":"Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"393","author":"U Bavendiek","year":"2025","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1002\/ejhf.3428","article-title":"Efficacy and safety of low-dose digoxin in patients with heart failure. Rationale and design of the DECISION trial","volume":"26","author":"DJ Veldhuisen","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2025.102675","article-title":"Digoxin Reduces Pulmonary Artery Pressure in Patients With Heart Failure: A Report of the CardioMEMS Database","volume":"13","author":"J Lindenfeld","year":"2025","journal-title":"JACC Heart Fail"},{"issue":"12","key":"ref19","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/ejhf.70022","article-title":"Low-dose digoxin improves cardiac function in patients with heart failure, preserved ejection fraction and atrial fibrillation \u2013 the RATE-AF randomized trial","volume":"27","author":"KV Bunting","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1016\/S0140-6736(14)61373-8","article-title":"Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis","volume":"384","author":"D Kotecha","year":"2014","journal-title":"Lancet"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2676-2529.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T22:38:37Z","timestamp":1780094317000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2676-2529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":20,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,5,29]]},"published-print":{"date-parts":[[2026,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2676-2529","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]}}}